Skip to main content

Effect of Transcranial Direct Current Stimulation of the Motor Cortex on Visceral Pain in Patients with Hepatocellular Carcinoma.

Research Authors
Ibrahim NM1, Abdelhameed KM1, Kamal SMM2, Khedr EMH3, Kotb HIM1.
Research Journal
Pain Med. 2018 Mar 1;19(3):550-560. doi: 10.1093/pm/pnx087.
Research Member
Research Publisher
Oxiford Academic
Research Rank
1
Research Vol
2018 Mar 1;19(3):550-560.
Research Website
pubmed central
Research Year
2018
Research_Pages
2018 Mar 1;19(3):550-560.
Research Abstract

Abstract
OBJECTIVE:
Hepatocellular carcinoma (HCC) is frequently associated with visceral pain. Transcranial direct current stimulation (tDCS) has been proven to reduce chronic pain; however, its effectiveness in malignant visceral pain is unknown. This study aimed to investigate the effects of tDCS in patients with visceral pain due to HCC.

DESIGN:
This is a randomized, sham-controlled, double-blind, prospective study. Forty patients with visceral pain due to HCC were enrolled and randomly assigned into two groups: a real and a sham group; tDCS was applied over the primary motor area (M1) for 10 consecutive days (2 mA, 30 minutes). Patient's pain was evaluated by visual analog scale (VAS) and verbal descriptor scale (VDS) and for depression by Hamilton rating scale (HAM-D). Evaluation was done at prestimulation, after the first, fifth, and 10th sessions, and one month after the end of stimulation sessions.

RESULTS:
Real tDCS showed a reduction of VDS (P = 0.001, F = 4.01) and VAS (P = 0.001, F = 6.817) for HAM-D (P = 0.012, F = 5,077); the effect started from the fifth session and continued to one month after stimulation, while in the sham group the effect persisted for five days only. Percentage reduction in all scales in the real group after the 10th session was as follows: VDS P = 0.008, VAS P = 0.001, HAM-D = 0.001; for one month after the end of stimulation, it was as follows: VDS P = 0.001, VAS P = 0.037, HAM-D = 0.002.

CONCLUSIONS:
tDCS proved to be an effective and clinically relevant therapeutic strategy for visceral pain due to HCC.

TRIAL REGISTRATION:
ClinicalTrials.gov NCT02928237.